The help of my wife, Yu-His Chen, MD, in preparing this manuscript is acknowledged with gratitude and affection.

13. Silvestris F, Cafforio P, Tucci M, et al.: Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99:1305, 2002.

14. Nemeth E, Rivera S, Gabayan V, et al.: Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271, 2004.

15. Beguin Y, Yerna M, Loo M, et al.: Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648, 1992.

16. Ludwig H, Fritz E, Kotzmann H, et al.: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693, 1990.

17. Singh A, Eckardt KU, Zimmermann A, et al.: Increased plasma viscosity as a reason for inappropriate erythro-poietin formation. J Clin Invest 91:251, 1993.

18. Alexanian R: Blood volume in monoclonal gammopa-thy. Blood 49:301, 1977.

19. Atkins MB, Kappler K, Mier JW, et al.: Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 86:1288, 1995.

20. Hoffbrand AV, Hobbs JR, Kremenchuzky S, et al.: Incidence and pathogenesis of megaloblastic erythro-poiesis in multiple myeloma. J Clin Pathol 20:699, 1967.

21. Baatout S: Interleukin-6 and megakaryocytopoiesis: an update. Ann Hematol 73:157, 1996.

22. Kosmo MA, Gale RP: Plasma cell leukemia. Semin Hematol 24:202, 1987.

23. Greipp PR, Raymond NM, Kyle RA, et al.: Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65:305, 1985.

24. Bartl R, Frisch B, Burkhardt T, et al.: Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 51:361, 1982.

25. Krzyzaniak RL, Buss DH, Cooper MR, et al.: Marrow fibrosis and multiple myeloma. Am J Clin Pathol 89:63, 1988.

26. Vacca A, Ribatti D, Roncali L, et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503, 1994.

27. Castell JV, Gomez-Lechon MJ, David M, et al.: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242:237, 1989.

28. Moshage HJ, Kleter BE, van Pelt JF, et al.: Fibrinogen and albumin synthesis are regulated at the transcrip-tional level during the acute phase response. Biochim Biophys Acta 950:450, 1988.

29. Chen Y, Magalhaes MC: Hypoalbuminemia in patients with multiple myeloma. Arch Intern Med 150:605, 1990.

30. Greipp PR, Lust JA, O'Fallon WM, et al.: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382, 1993.

31. Dimopoulos MA, Barlogie B, Smith TL, et al.: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115:931, 1991.

32. Merlini G, Fitzpatrick LA, Siris ES, et al.: A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol 4:185, 1984.

33. Perkins HA, MacKenzie HR, Fundenberg HH: Hemostatic defects in dysproteinemias. Blood 35:695,

0 0

Post a comment